# Peter Schmid

Source: https://onco.cc/people/peter-schmid/  
OnCo record `peter-schmid` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KEYNOTE-522 and IMpassion130, the trials that brought immunotherapy into triple-negative breast cancer.

## Summary

Peter Schmid was principal investigator of IMpassion130, the first positive immunotherapy trial in breast cancer, and of KEYNOTE-522, which showed neoadjuvant pembrolizumab with chemotherapy raises pathological complete response and improves event-free and overall survival in stage II-III TNBC. KEYNOTE-522 is now the global standard for early TNBC. He leads experimental cancer medicine at Barts and continues to run immunotherapy and ADC combination trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: tnbc; immunotherapy; trialist
- Role: Professor of Cancer Medicine and Lead, Centre for Experimental Cancer Medicine, Barts Cancer Institute
- Specialisms: Triple-negative breast cancer; Immunotherapy; Neoadjuvant therapy; Early drug development

## Sources

- Barts Cancer Institute: https://www.bartscancer.london/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Schmid%20P%5BAuthor%5D%20pembrolizumab%20triple-negative

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Barts Cancer Institute / Barts Health NHS Trust](https://onco.cc/institutions/barts-cancer-institute/)
- trials: [IMpassion130](https://onco.cc/trials/impassion130/), [KEYNOTE-522](https://onco.cc/trials/keynote-522/)
- key papers: [Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial](https://onco.cc/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/), [Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial](https://onco.cc/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/), [Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial](https://onco.cc/key-papers/paper-tropion-breast02-ann-oncol-2026/), [Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer](https://onco.cc/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/), [KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-522-nejm-2022/), [PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/peter-schmid.json